Investors Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 33,848 call options on the company. This represents an increase of approximately 52% compared to the average volume of 22,258 call options.

Analysts Set New Price Targets

Several research analysts have weighed in on TEVA shares. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $12.00 to $19.00 in a research note on Monday, February 12th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Barclays lifted their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Finally, Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price target for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $13.98 on Thursday. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $14.47. The stock’s 50-day moving average is $13.57 and its two-hundred day moving average is $11.51. The firm has a market cap of $15.67 billion, a P/E ratio of -29.74, a price-to-earnings-growth ratio of 1.68 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The business had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. On average, analysts anticipate that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Richard D. Francis sold 74,530 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the sale, the chief executive officer now directly owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The disclosure for this sale can be found here. Insiders have sold 358,972 shares of company stock worth $4,739,820 over the last 90 days. 0.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 184,642.3% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after buying an additional 27,696,340 shares during the last quarter. Sound Shore Management Inc CT bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $80,791,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 14.4% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock valued at $276,000,000 after purchasing an additional 3,413,100 shares during the last quarter. FMR LLC increased its stake in shares of Teva Pharmaceutical Industries by 3,553.8% in the third quarter. FMR LLC now owns 2,564,339 shares of the company’s stock worth $26,156,000 after purchasing an additional 2,494,156 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares during the period. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.